Protalix BioTherapeutics Inc (AMEX:PLX) does about 1.13M shares in volume on a normal day but saw 1010787 shares change hands in the recent trading day. The company now has a market cap of 117.82M USD. Its current market price is $1.48, marking an increase of 0.68% compared to the previous close of $1.47. The 52 week high reached by this stock is $3.10 whilst the lowest price level in 52 weeks is $0.82.
Protalix BioTherapeutics Inc (PLX) has a 20-day trading average at $1.4775 and the current price is -52.26% off the 52-week high compared with 80.18% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.8196 and its 200-day simple moving average is $1.8893. If we look at the stock’s price movements over the week, volatility stands at 4.75%, which increases to 6.79% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 44.06 to suggest the stock is neutral.
The consensus objective for the share price is $15.00, suggesting that the stock has a potential upside of 90.13% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on June 08, 2020 when H.C. Wainwright reiterated the stock to “Buy” and issued a price target of between $3 and $11. Rodman & Renshaw initiated its price target at $3.50.
The current price level is 0.17%, -18.66%, and -21.66% away from its SMA20, SMA50, and SMA200 respectively, with the PLX price moving above the 50-day SMA on current market day. Its price is 42.31% year-to-date and -21.28% over the past year.
To reach the target analysts have set, the stock logically needs to grow 90.13 percent from here.
Outstanding shares total 78.13M with insiders holding 10.39% of the shares and institutional holders owning 10.78% of the company’s common stock. The company has a return on investment of 7.97% and return on equity of 10.42%. The price to earnings ratio (P/E ratio) amounts to 35.24 while the forward price to earnings ratio is 3.29. The beta has a value of -0.21. Price to book ratio is 2.56 and price to sales ratio is 1.97.
